Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn`s Disease

Study:

A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn`s Disease

Rationale:

n/a

Purpose:

The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn`s Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Crohn`s Disease Drug: Epanova™ (Omega-3 Free Fatty Acids) Phase 3

Verified by Tillotts Pharma AG October, 2005

Sponsored by: Tillotts Pharma AG
Information provided by: Tillotts Pharma AG
ClinicalTrials.gov identifier: NCT00074542

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.